Your session is about to expire
← Back to Search
PARP Inhibitor
Talazoparib for Advanced Breast Cancer
Phase 2
Recruiting
Led By Melinda Telli
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Measurable disease per RECIST v1.115 (CT CAP with contrast and bone scan or positron emission tomography computer tomography (PET/CT) with IV contrast needed within 28 days of Cycle 1 Day 1. If patients have a history of brain metastases, a MRI brain or CT head with contrast is required
Histologically confirmed metastatic or recurrent HER2 negative breast cancer (IHC or fluorescence in situ hybridization (FISH) per ASCO/CAP guidelines)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
Study Summary
This trial is testing if talazoparib is safe and effective for treating advanced breast cancer associated with a mutation in the PALB2 gene.
Who is the study for?
This trial is for adults with advanced breast cancer linked to a PALB2 gene mutation. Participants can have had up to three prior treatments, must be able to take pills, and women of childbearing age need a negative pregnancy test and use contraception. People are excluded if pregnant, breastfeeding, previously treated with PARP inhibitors, or have certain brain metastases or other conditions that could affect safety.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of Talazoparib Tosylate in treating advanced breast cancer associated with PALB2 mutations. It's an oral medication given as monotherapy, meaning it's used alone without combining it with other drugs.See study design
What are the potential side effects?
While not specified here, common side effects of Talazoparib may include fatigue, blood cell count changes leading to increased infection risk or bruising/bleeding problems, nausea and vomiting, hair loss (alopecia), headache and potential kidney function issues.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer can be measured by scans and I've had the required scans recently.
Select...
My breast cancer is confirmed to be HER2 negative.
Select...
My cancer did not worsen after or during my last platinum-based treatment.
Select...
I have had up to 3 treatments for my advanced illness.
Select...
My kidney function is within the normal range.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
My side effects from previous cancer treatments are mild, except for hair loss and some nerve pain.
Select...
My blood counts meet the required levels for the study.
Select...
My cancer has a harmful PALB2 mutation confirmed by a specific test.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Objective response rate (ORR)
Secondary outcome measures
Clinical Benefit Rate (CBR)
Number of participants with Treatment-related Adverse Events ≥ Grade 3
Patient-reported Quality of Life (QoL)
+1 moreSide effects data
From 2022 Phase 2 trial • 21 Patients • NCT0240134745%
Fatigue
45%
Nausea
35%
Platelet count decreased
35%
Constipation
25%
Alkaline phosphatase increased
25%
Neutropenia
25%
Anorexia
25%
Back pain
20%
Anemia
15%
Vomiting
15%
Thrombocytopenia
15%
Aspartate Amino Transferase increased
15%
Alanine aminotransferase increased
15%
Pain in extremity
15%
Pain
15%
Dyspnea
15%
Cough
15%
Alopecia
10%
Shoulder Pain
10%
Headache
10%
Hyponatremia
10%
Abdominal pain
10%
Diarrhea
10%
Fever
10%
Myalgia
5%
Flu-like symptoms
5%
Stomach pain
5%
Mucositis oral
5%
Bloating
5%
Lymphedema
5%
Trismus
5%
Peripheral sensory neuropathy
5%
Allergic rhinitis
5%
Weakness in extremities, right side
5%
Heartburn
5%
Facial muscle weakness
5%
Intracranial masses, supratentorial and infratentoria
5%
Hypocalcemia
5%
Bone pain
5%
Pneumothorax, post-lung biopsy
5%
Edema limbs (peripheral edema)
5%
Weight loss
5%
Deep venous thrombosis
5%
Weakness in extremity, right leg, progressing
5%
Anxiety
5%
Epistaxis
5%
Sore throat
5%
Rash, maculo-papular
5%
Thromboembolic event
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort B - HER2-negative Solid Tumor
Cohort A - Triple-negative Breast Cancer
Trial Design
1Treatment groups
Experimental Treatment
Group I: Talazoparib ArmExperimental Treatment1 Intervention
Talazoparib 1 mg/day for 24 cycles (28 days per cycle), continuing until withdrawn or discontinued, eg, until RECIST 1.1 progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Talazoparib Tosylate
2015
Completed Phase 2
~30
Find a Location
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,390 Previous Clinical Trials
17,340,697 Total Patients Enrolled
60 Trials studying Breast Cancer
111,150 Patients Enrolled for Breast Cancer
PfizerIndustry Sponsor
4,568 Previous Clinical Trials
10,911,856 Total Patients Enrolled
110 Trials studying Breast Cancer
36,374 Patients Enrolled for Breast Cancer
Melinda TelliPrincipal InvestigatorStanford Universiy
1 Previous Clinical Trials
25 Total Patients Enrolled
1 Trials studying Breast Cancer
25 Patients Enrolled for Breast Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cancer can be measured by scans and I've had the required scans recently.My liver functions are within the required limits.I am a woman who can have children, have a negative pregnancy test, and agree to more tests during the study.I can take pills by mouth.My breast cancer is confirmed to be HER2 negative.My cancer did not worsen after or during my last platinum-based treatment.I have had up to 3 treatments for my advanced illness.I have been treated with a PARP inhibitor before.I have brain metastases or leptomeningeal carcinomatosis but am stable and not on high-dose steroids.I am 18 years old or older.I have a harmful BRCA1 or BRCA2 gene mutation.You have a serious infection or bleeding disorder that could affect your ability to take part in the study safely.My kidney function is within the normal range.My breast cancer can be treated with the aim of curing it.You cannot have taken any experimental medications within 28 days before the start of the study.I can take care of myself and am up and about more than half of my waking hours.I have an active hepatitis B or C infection.I have not had radiation therapy in the last 14 days.My blood counts meet the required levels for the study.I have not had major surgery in the last 3 weeks.My side effects from previous cancer treatments are mild, except for hair loss and some nerve pain.I haven't been treated for any cancer except skin cancer or early-stage cervical/breast cancer in the last 3 years.I am willing to use birth control during and for 3 months after the study.I can provide a sample of my tumor, either recent or from a past biopsy.My cancer has a harmful PALB2 mutation confirmed by a specific test.
Research Study Groups:
This trial has the following groups:- Group 1: Talazoparib Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many people are being approved for this clinical experiment?
"Unfortunately, this study is not taking on any more patients at the moment. The original posting was on January 1st 2023 and there have been no updates since November 9th 2022. However, if you're still interested in participating in clinical trials, there are 2702 active studies for breast cancer and 60 for Talazoparib Tosylate."
Answered by AI
Are there any dangers that patients should be aware of when taking Talazoparib Tosylate?
"While there is some data suggesting that Talazoparib Tosylate is safe, none of it points to the medication being effective. Consequently, our team at Power gave it a score of 2."
Answered by AI
Are people still being sought out to participate in this research?
"Data from clinicaltrials.gov reveals that this particular trial is no longer recruiting patients, as the last update was on November 9th, 2022. It's worth noting that there are 2762 other trials with open recruitment at this time."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger